TAR-200用于尿路上皮癌的III 期研究｜NCT05714202

一分钟看懂

这是一项关于尿路上皮癌的III 期研究，登记的药物或干预包括TAR-200；Cetrelimab；BCG Vesiculture，当前状态为研究进行中，已停止招募。登记地点显示中国北京、长春、长沙、成都等城市有研究中心记录。是否仍有名额以及是否值得进一步询问，需要向研究中心确认。

TAR-200；Cetrelimab；BCG Vesiculture · III 期

登记的基本范围为不限性别，年龄18 岁；另列出6项专业入选条件，需结合英文原文并由研究团队确认。

登记记录列出5项主要排除条件，具体医学含义需结合英文原文并由研究团队确认。

以下地点来自登记信息，不代表此刻仍有名额；请向研究中心确认最新情况。

Peking University First Hospital · 北京
Beijing Hospital · 北京
Beijing Luhe Hospital, Capital Medical University · 北京
The First Bethune Hospital of Jilin University · 长春
Hunan Province Cancer Hospital · 长沙
West China Hospital Sichuan University · 成都
Chongqing University Cancer Hospital · 重庆
People's Hospital of Deyang City · 德阳
Sun Yat Sen University Cancer Center · 广州
Zhejiang Provincial People's Hospital · 杭州
Sir Run Run Shaw Hospital Zhejiang University School of Medicine · 杭州
Nanjing Drum Tower Hospital · 南京
The First Affiliated Hospital of Ningbo University · 宁波
Ruijing Hospital Affiliated To Shanghai Jiaotong University School Of Medicine · 上海
Huadong Hospital Affiliated to Fudan University · 上海
Shengjing Hospital Of China Medical University · 沈阳
The Second Hospital Of Tianjin Medical University · 天津
The First Affiliated Hospital of Wenzhou Medical University · 温州
TongJi Hospital of TongJi Medical College of Huazhong University of Science & Technology · 武汉
First Affiliated Hospital of Medical College of Xi'an Jiaotong University · 西安
Yantai Yuhuangding Hospital · 烟台
Henan Cancer Hospital · 郑州

* Histologically confirmed initial diagnosis by local pathology (within 90 days of the most recent signed informed consent) of high grade non-muscle invasive bladder cancer (HR-NMIBC) (high-grade Ta, any T1 or carcinoma in-situ \[CIS\]), in participants who ar
* BCG-naïve (participants who have not received prior intravesical BCG or who previously received but stopped BCG more than 3 years before date of randomization are eligible)
* All visible papillary disease must be fully resected (absent) prior to date of randomization and documented at baseline cystoscopy. Local urine cytology at screening must be negative or atypical (for high-grade urothelial carcinoma \[HGUC\]) for patients wit
* Eastern Cooperative Oncology Group (ECOG) performance status Grade 0, 1, or 2
* All adverse events associated with any prior surgery and/or intravesical therapy must have resolved to common terminology criteria for adverse events (CTCAE) version 5.0 Grade less than (\<) 2 prior to date of randomization
* Participants must be willing to undergo all study procedures

请继续确认中心是否启动、疾病分型、既往治疗、检查费用和知情同意安排。

登记号：NCT05714202；登记信息更新于 2026-09-25。